$IVVD

Lee Timothy Edward sold $32K of IVVD

Lee Timothy Edward (Chief Commercial Officer) sold 40,780 shares of Invivyd, Inc. (IVVD) at an average of $0.78 ($0.72–$0.84) across 2 trades over 2026-08-17 to 2026-08-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lee Timothy Edward
Published Aug 19, 2026, 12:10 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 12:42 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IVVD
Neutral
high confidence
Mentioned
$IVVD
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IVVDNeutralLow
01

Why it matters

The disclosed fact is the sale size, price range, and that it was executed under a pre-arranged 10b5-1 plan; the text does not include any new company fundamentals.

02

Market read

Traders may note the insider sale for sentiment, but the 10b5-1 designation reduces the likelihood of a fundamental repricing catalyst.

03

What to watch

The article does not state total insider holdings value, sale frequency over time, or whether other insiders sold, limiting inference from this single transaction.

Relevance 2/10Novelty 3/10Timing: Filed 2026-08-18 for sales executed 2026-08-17 to 2026-08-18.

Background

The article reports an SEC Form 4 insider transaction for Invivyd, Inc. (IVVD) by its Chief Commercial Officer.

Company-level read

Ticker impact

$IVVDNeutralHigh confidence
Context

Invivyd CCO Lee Timothy Edward sold about 40,780 shares in open-market transactions priced $0.7220 to $0.8429 per share.

Expected impact

Limited near-term impact; any reaction is likely muted unless paired with other company-specific news.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly pre-arranged under Rule 10b5-1, with no accompanying operational or financial disclosure in the text.

Market effects

No sector read-through is provided beyond a single-company insider sale.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still coincide with internal caution, which some traders may interpret as bearish.

Key entities

  • Invivyd, Inc.

    Subject of the Form 4 insider sale disclosure.

  • Lee Timothy Edward

    Chief Commercial Officer who sold shares in open-market transactions.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IVVDMedAI 8/10

Invivyd launches phase 2 trial of VYD2311 for long COVID

Invivyd (NASDAQ:IVVD) initiated a Phase 2 trial of VYD2311 for Long COVID and Post-Vaccination Syndrome. The trial will enroll 130 participants and assess safety, tolerability, and efficacy over 90 days. VYD2311 has shown in vitro potency against SARS-CoV-2 variants. Initial data is expected in mid-2027. The trial is part of Invivyd’s broader REVOLUTION clinical program.

$IVVDMedAI 8/10

Invivyd, Inc. (IVVD) Begins Phase 2 Trial of VYD2311 for Long COVID/PVS

Invivyd, Inc. (IVVD) has initiated a Phase 2 trial, FLINTLOCK, to evaluate the safety and efficacy of VYD2311, a monoclonal antibody, in treating Long COVID and Post-Vaccination Syndrome. The trial involves ~130 participants and will assess high-dose VYD2311 against a placebo over 90 days. VYD2311 has shown strong antiviral potency against SARS-CoV-2 variants. Success could open a new treatment market, addressing a significant unmet need.

$IVVDMedAI 8/10

Millions live with long COVID. A trial will test an antibody as a possible treatment.

Invivyd (IVVD) and the SPEAR Study Group initiated the FLINTLOCK Phase 2 trial to test the monoclonal antibody VYD2311 for treating Long COVID and Post-Vaccination Syndrome. The trial will evaluate safety, efficacy, and pharmacokinetics over 90 days. VYD2311 has shown antiviral potency against all SARS-CoV-2 variants tested. Initial data is expected in mid-2027.

$IVVDMedAI 9/10

Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine…

Invivyd, Inc. (IVVD) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311 • VYD2311 met all primary and secondary endpoints comparing

$IVVDMedAI 8/10

Invivyd Reports VYD2311 Meets Primary Safety Endpoints In Phase 3 Trial

Invivyd (IVVD) reported that its COVID-19 monoclonal antibody VYD2311 met primary safety endpoints in the Phase 3 LIBERTY study, showing favorable safety and tolerability compared to an mRNA vaccine. The study enrolled 210 healthy adults, with 56.5% of VYD2311 recipients experiencing adverse events versus 91.4% for the vaccine. The company plans to use the data to support a BLA submission to the FDA. IVVD stock closed at $0.95, up 1.69%, and is trading at $0.99 in pre-market.

$IVVDMed

Invivyd Reports Second Quarter 2026 Financial Results and Recent

Invivyd, Inc. (IVVD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights • Achieved Q2 2026 PEMGARDA® (pemivibart) net product revenue of $14.3 million, representing 21% growth versus Q2 2025 net product revenue of $11.8 million • Completed rapid enrollme